A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...

An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to ... Studies for additional therapeutic ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's ... donanemab." While the phase 2 TRAILBLAZER-ALZ trial included more than 100 patients on the drug ...

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busting drug ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.